Literature DB >> 3997250

Biologically active antibodies elicited by a synthetic circumsporozoite peptide of Plasmodium knowlesi administered in saline with a muramyl dipeptide derivative.

E R Clough, F M Audibert, J W Barnwell, D H Schlesinger, R Arnon, L A Chedid.   

Abstract

A synthetic peptide whose sequence was derived from the circumsporozoite protein of Plasmodium knowlesi coupled to bovine gamma globulin has been shown to be immunogenic when administered with Freund complete adjuvant. The present experiments were designed to test the immunogenicity of the peptide when attached to a tetanus toxoid carrier and administered with alum or murabutide, both acceptable clinical adjuvants. In both cases, the use of an adjuvant increased the levels of circulating anti-peptide antibodies over those observed when no adjuvant was used. However, when the antisera were tested for reactivity with the native protein, animals of the group receiving the conjugate associated with murabutide always had titers greatly exceeding those observed in animals that received the conjugate with alum. Moreover, the sera of the murabutide-treated group were shown to be more active in eliciting shedding of the circumsporozoite protein than were sera of animals of the Freund complete adjuvant-treated group. The use of tetanus toxoid in secondary immunizations could be eliminated when the mice primed with peptide-tetanus toxoid and murabutide were boosted with a polymer of the peptide. The results indicate that the synthetic malarial peptide-tetanus toxoid conjugate is capable of stimulating high levels of biologically active antibodies only when administered with murabutide.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3997250      PMCID: PMC261281          DOI: 10.1128/iai.48.3.839-842.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Characterization of sporozoite surface antigens by indirect immunofluorescence: detection of stage- and species-specific antimalarial antibodies.

Authors:  E Nardin; R W Gwadz; R S Nussenzweig
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

2.  Structural similarities among the protective antigens of sporozoites from different species of malaria parasites.

Authors:  F Santoro; A H Cochrane; V Nussenzweig; E H Nardin; R S Nussenzweig; R W Gwadz; A Ferreira
Journal:  J Biol Chem       Date:  1983-03-10       Impact factor: 5.157

3.  Antibodies to the protective antigen of Plasmodium berghei sporozoites prevent entry into cultured cells.

Authors:  M R Hollingdale; F Zavala; R S Nussenzweig; V Nussenzweig
Journal:  J Immunol       Date:  1982-04       Impact factor: 5.422

4.  Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites.

Authors:  J Vanderberg; R Nussenzweig; H Most
Journal:  Mil Med       Date:  1969-09       Impact factor: 1.437

5.  Vaccination of experimental monkeys against Plasmodium falciparum: a possible safe adjuvant.

Authors:  W A Siddiqui; D W Taylor; S C Kan; K Kramer; S M Richmond-Crum; S Kotani; T Shiba; S Kusumoto
Journal:  Science       Date:  1978-09-29       Impact factor: 47.728

6.  Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites.

Authors:  R W Gwadz; A H Cochrane; V Nussenzweig; R S Nussenzweig
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

7.  ANTIBODIES TO BRADYKININ AND ANGIOTENSIN: A USE OF CARBODIIMIDES IN IMMUNOLOGY.

Authors:  T L GOODFRIEND; L LEVINE; G D FASMAN
Journal:  Science       Date:  1964-06-12       Impact factor: 47.728

8.  Identification and chemical synthesis of a tandemly repeated immunogenic region of Plasmodium knowlesi circumsporozoite protein.

Authors:  G N Godson; J Ellis; P Svec; D H Schlesinger; V Nussenzweig
Journal:  Nature       Date:  1983 Sep 1-7       Impact factor: 49.962

9.  Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity.

Authors:  L A Chedid; M A Parant; F M Audibert; G J Riveau; F J Parant; E Lederer; J P Choay; P L Lefrancier
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

10.  Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes.

Authors:  F Zavala; A H Cochrane; E H Nardin; R S Nussenzweig; V Nussenzweig
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

View more
  4 in total

1.  Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier.

Authors:  L D Lise; D Mazier; M Jolivet; F Audibert; L Chedid; D Schlesinger
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

2.  Induction of biologically active antibodies by a polyvalent synthetic vaccine constructed without carrier.

Authors:  M E Jolivet; F M Audibert; H Gras-Masse; A L Tartar; D H Schlesinger; R Wirtz; L A Chedid
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

3.  Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195.

Authors:  G S Hui; L Q Tam; S P Chang; S E Case; C Hashiro; W A Siddiqui; T Shiba; S Kusumoto; S Kotani
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

4.  New approaches for control of infections using synthetic or semi-synthetic constructs containing MDP.

Authors:  L Chedid; F Audibert
Journal:  Springer Semin Immunopathol       Date:  1985
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.